Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of niraparib versus physician's choice chemotherapy in previously treated HER2-negative germline BRCA-mutated breast cancer
2013-000684-85Phase 3Completed
- Sponsor
- TESARO, Inc.
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of niraparib in breast cancer (2 arms), sponsored by TESARO, Inc. Primary endpoint: Progression-free survival. Started Dec 2013; status: completed.
02
Drugs
niraparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-000684-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000684-85.